Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alios BioPharma Inc.

This article was originally published in Start Up

Executive Summary

Alios BioPharma aims to create an improved version of interferon--the only drug that could be considered a broad-spectrum antiviral--to help patients who do not respond well to currently marketed forms of the protein. Alios also plans to develop a small-molecule drug that can be given orally yet carry out a key function of the interferon response-degrading viral genomes. Such a drug could potentially treat influenza, hepatitis C and B, HIV, and a host of other viruses.
Advertisement

Related Content

Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
The A-List: 2009's Trend-Shaping Series A Financings
The A-List: 2009's Trend-Shaping Series A Financings
Start-Up Previews (06/2009)
Marinomed Biotechnologie GMBH
Immune Targeting Systems Ltd.
Vivaldi Biosciences Inc.
Start-Ups Set Sights on Flu
Start-Ups Set Sights on Flu

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel